The probability of relapse after complete remission of acute myeloid leukemia type m2 is related to the severity of the disease, the treatment regimen, and the patient’s physical condition. In general, 30% to 40% of patients may experience disease relapse. The probability of relapse after complete remission of AML type m2 is generally higher, as this type of leukemia is more difficult to treat, and the probability of relapse after complete remission is higher than that of other types of leukemia. The initial remission rate of adult AML m2 is generally 50%~70%, and without subsequent consolidation, most patients will relapse within 1~2 years. Therefore, patients need to continue to be consolidated with intensive therapy, such as high-dose cytarabine regimens, to reduce the rate of disease relapse after remission and prolong survival. For patients with AML type m2, the probability of relapse is related to the severity of the disease, treatment, and the patient’s own condition, and the specific treatment needs to be carried out under the guidance of a physician.